September 12, 9:55 AM
Cowen & Co. analyst Boris Peaker maintains Emergent BioSolutions (NYSE:EBS) with a Market Perform and lowers the price target from $30 to $29.
September 6, 10:51 AM
Emergent BioSolutions (NYSE: EBS) has dosed first patient in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV in healthy subjects. EBS-LASV is a recombinant VSV-vectored Lassa virus vaccine candidate being evaluated for prevention of disease caused by Lassa virus infection.